PechaKucha Versus PowerPoint for Parkinson's Disease Education in Nurses
August 29, 2026 updated by: Gonul Bodur, Istanbul University - Cerrahpasa
PechaKucha Versus PowerPoint in Nursing Education: A Quasi-Experimental Study
This study compared the effects of PechaKucha and traditional PowerPoint presentation techniques used for Parkinson's disease education on nurses' knowledge and awareness levels.
The study used a two-group pretest-posttest quasi-experimental design.
A total of 72 nurses were assigned to the PechaKucha intervention group (n=36) or the PowerPoint control group (n=36) using 1:1 block randomization.
Both groups received Parkinson's disease education with identical educational content and learning objectives.
The PechaKucha presentation consisted of 20 slides automatically advancing every 20 seconds, whereas the PowerPoint presentation was delivered using a conventional flexible-paced format.
Parkinson's disease knowledge and awareness were assessed before and immediately after the educational intervention.
The study aimed to determine whether the presentation technique influenced nurses' knowledge and awareness following Parkinson's disease education.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
72
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Istanbul
-
Istanbul, Istanbul, Turkey (Türkiye), 34668
- Sultan Abdulhamid Han Training and Research Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
Appointed to the study hospital within the previous 12 months. Actively working as a nurse at the time of the study. Voluntarily agreed to participate in the study and provided written informed consent.
Exclusion Criteria:
None specified.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: PechaKucha Group
Participants in this arm received Parkinson's disease education using the PechaKucha presentation technique.
The presentation consisted of 20 slides that automatically advanced every 20 seconds, with a total presentation duration of 6 minutes and 40 seconds.
|
Participants received Parkinson's disease education using the PechaKucha presentation technique.
The presentation consisted of 20 slides that automatically advanced every 20 seconds, resulting in a total presentation duration of 6 minutes and 40 seconds.
|
|
Active Comparator: PowerPoint Group
Participants in this arm received Parkinson's disease education using a traditional PowerPoint presentation.
The presentation consisted of 23 slides, was delivered with flexible pacing, and lasted approximately 30-35 minutes.
|
Participants received Parkinson's disease education using a traditional PowerPoint presentation.
The presentation consisted of 23 slides, was delivered with flexible pacing, and lasted approximately 30-35 minutes.
The educational content and learning objectives were identical to those used in the PechaKucha group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Parkinson's Disease Knowledge Score
Time Frame: Baseline and immediately after the educational intervention
|
Parkinson's disease knowledge was assessed using the 20-item Parkinson's Disease Knowledge Test.
Each correct answer was scored as 1 and each incorrect answer as 0, yielding a total score ranging from 0 to 20.
Higher scores indicate greater knowledge of Parkinson's disease.
Change in knowledge was evaluated by comparing pre-intervention and immediate post-intervention scores.
|
Baseline and immediately after the educational intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Parkinson's Disease Awareness Score
Time Frame: Baseline and immediately after the educational intervention
|
Parkinson's disease awareness was assessed using the 17-item Awareness Assessment Form.
Items were rated on a 5-point Likert scale, yielding a total score ranging from 17 to 85. Higher scores indicate greater awareness of Parkinson's disease.
Change in awareness was evaluated by comparing pre-intervention and immediate post-intervention scores.
|
Baseline and immediately after the educational intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 2, 2026
Primary Completion (Actual)
February 14, 2026
Study Completion (Actual)
April 30, 2026
Study Registration Dates
First Submitted
August 29, 2026
First Submitted That Met QC Criteria
August 29, 2026
First Posted (Actual)
September 2, 2026
Study Record Updates
Last Update Posted (Actual)
September 2, 2026
Last Update Submitted That Met QC Criteria
August 29, 2026
Last Verified
August 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PKPD-2026-82
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.